Home  /  Resource Library  /  Long term efficacy of first line ibrutinib treatment for chronic lymphocytic leukaemia in patients with TP53 aberrations: a pooled analysis from four clinical trials

Long term efficacy of first line ibrutinib treatment for chronic lymphocytic leukaemia in patients with TP53 aberrations: a pooled analysis from four clinical trials

Pooled analysis study examined ibrutinib for treatment of CLL with TP53 mutation.